We’re a 501c3 nonprofit conducting and supporting research to help people live better and longer lives.
Here at Norn we’re achieving our Mission through…
Funding Aging Research…
Impetus Grants is our in-house fund for high-risk, high-reward research. We provide up to $500k within 3 weeks for scientists to start working on the most important problems in aging biology.
-
Since inception in 2021, Impetus has funded 146 projects with over $34 Million USD in funds.
In our most recent, Round 3; we reviewed over 1000 applications and gave out close to $10M for 34 selected projects.
-
All academic/non-profit researchers are welcome to apply including trainees and students, from anywhere in the world.
Grants have been awarded to professors, postdocs, graduate students, and more, many projects coming from labs that are new to the aging space.
-
We fund high-impact projects with the potential to accelerate the field but are typically unlikely to get funding through existing institutions.
This includes non-research projects and ones that stress-test assumptions in aging, develop new tools and methodologies, discover new ways to reverse aging processes and ones that translate preclinical findings.
-
Our ability to create an impact in aging biology is powered through donations. Visit our Donate page to learn more about Impetus and our current impact.
Please contact us to arrange for significant donations
Apply:
Applications are currently closed.
Impetus Grants is conducted in rounds. To stay up to date on our announcements including our next rounds, sign up for the Impetus Grants via our Email List (we won’t spam you otherwise).
curating High-Potential Actors...
Longevity Nexus
Our action-oriented group of curated high-potential actors, ranging from scientists to policy experts, committed to advancing the longevity field.
Nexus brings people together to connect with each, discuss findings in the longevity field, and ultimately create impact by producing high-quality reviewed resources for the public and take on meaningful projects within Norn Group.
Learn more and Apply to join Nexus below.
About NexusTalent Bridge
Opening doors for committed agents and talent in aging research outside of the USA.
Our revived Talent Bridge program provides personal and project funding for those looking to or already engaged in a call to action or another bottleneck of importance.
Agency and ambition are key qualities of Talent Bridge Award recipients. We provide resources for them to relocate and maximize their impact.
Learn more about Talent Bridge Below
About Talent Bridgeall to produce Outcome-Driven results ...
Calls to Action:
We're looking for people to collaborate and work on these... If interested get in touch with us.
Developing and validating minimally invasive biomarkers for aging. A community research project to create targets for the biology of aging and dramatically reduce timelines for Clinical Trials.
Can aging clocks accelerate discoveries in aging biology by serving as precise biomarkers for lifespan and health outcomes? We propose a Clocks Assessment Program (CAP) to validate the predictive power of methylation clocks as tools, helping streamline research and fast-track the development of therapies for age-related diseases.
Clinical Trials in Aging
How can we leverage innovations in clinical trials such as centralized infrastructure, platform trials and risk-based monitoring to improve efficiency? Proposals to streamline drug development for age-related diseases and aging drugs.
Impactful Experiment - Prospective Study for Predictive Lifespan
Run the first definitive test on whether any current aging clocks can predict lifespan.
Disease-Animal Model Map
A disease-animal model map can help researchers identify the most suitable animal models for their target diseases, and result in optimized experimental accuracy, reduced costs, and accelerating target therapy research.
These are questions we believe need answers, reach out to us if you are working on these.
Are there drugs associated with extension of latest child birth based on medical records?
Identifying drugs that extend childbearing age could reveal targets for reproductive longevity, offering clues for aging interventions and improving quality of life in advanced age.
"Obesity is a risk factor for a lot of diseases; Aging is much worse" - Are there appropriate statistics for this statement? e.g. What is the hazard ratio of obesity across 5-15 diseases, and then ten years of age for 5-15 diseases?
Comparing obesity and aging allows us to quantify their impact on disease risk via multiple diseases' hazard ratios. This can help us priortize interventions targeting aging as a broader more influential health determinant.
What are Effect Sizes for Rapamycin Trials?
One of the many obstacles to run Rapamycin Trial is a need for better effect size estimates. We believe the steps to estimate the effect size are to:
- Define the mTOR/Rapamycin pathway: Investigate similar pathways
- Collect animal study results on drugs on those similar pathways
- Collect clinical trial results on drugs on those similar pathways
- Collect Rapamycin animal study results and extrapolate data
Resources:
A video primer presentation by Martin Borch Jensen built for people new to the field of aging biology. During this presentation Martin defines aging and its associated problems, the various biological mechanisms of aging, and current challenges plaguing the field.
The journal club goes through landmark discoveries and topics in aging biology, with a focus on primary research papers.
It’s intended for people who have gained familiarity with topics within aging biology and want to refine their understanding of what’s possible and what’s next.
Content includes link to papers, slides from presenters, and notes from our discussions.
Chronologically going through these topics highlight how young the field is (a couple of decades), and how even major conference topics often arose from a single bold experiment.
We read between the lines to evaluate strong claims, deduce limitations, and discuss implications.
Contributions from Divya Cohen, Tara Mei, Madison Ueland, Kush Sharma, Lada Nuzhna, Martin Borch Jensen.
Norn Group’s mission is to maximize the probability that by 2060 we have interventions that will let a 60 year old live for another 60 years without a decline in health and function.
Read our thesis